Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease

Core Viewpoint - Nexalin Technology, Inc. has published a significant study demonstrating the effectiveness of its Deep Intracranial Frequency Stimulation (DIFS) technology in enhancing brain function and cognitive performance in patients with mild Alzheimer's disease, as reported in the Journal of Alzheimer's Disease [1][5]. Study Overview - The study involved 46 patients who were randomly assigned to receive either real DIFS or sham treatment over 30 one-hour sessions within three weeks, utilizing resting-state functional magnetic resonance imaging (rs-fMRI) to monitor brain activity changes [2]. Key Findings - Increased Neuronal Activity and Glucose Metabolism: Real DIFS treatment led to significant increases in fractional amplitude of low-frequency fluctuation (fALFF) in the prefrontal cortex, correlating with improved glucose metabolism, which is vital for cognitive function [3]. - Sustained Cognitive Benefits: Improvements in cognitive function were observed three months post-treatment, with increased neuronal activity in memory-related brain regions, indicating long-lasting effects of DIFS [3]. - Enhanced Brain Connectivity: The study showed improved regional homogeneity (ReHo) in specific frontal gyrus areas, suggesting better synchronization of neural activity and enhanced communication pathways in the brain [3]. - Correlations with Improved Blood Flow and Brain Function: Enhanced blood flow in critical regions was noted, correlating with increased neuronal activity and suggesting DIFS's potential to restore disrupted metabolic processes in Alzheimer's patients [3]. - Safe and Well-Tolerated Treatment: No serious side effects were reported, with only minor sensations experienced by participants, highlighting the treatment's safety profile for vulnerable populations [3]. Industry Context - With over 50 million people affected by Alzheimer's disease globally, projected to rise to over 113 million by 2050, there is a pressing need for innovative therapies that address cognitive decline's root causes [4]. - Current treatments mainly focus on symptom management, while Nexalin's DIFS technology aims to modulate brain activity and restore metabolic functions, presenting a new treatment avenue for Alzheimer's [4]. Company Insights - Nexalin's DIFS technology has shown significant improvements in cognitive function, as evidenced by gains in Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores, reinforcing the potential of non-invasive stimulation therapies in Alzheimer's treatment [5]. - The Chief Medical Officer of Nexalin expressed optimism regarding DIFS's ability to improve cognitive function in a well-tolerated manner, addressing underlying causes of cognitive decline [6]. - The CEO of Nexalin highlighted the study as a milestone for DIFS technology, emphasizing its potential to restore brain function and improve cognitive performance in Alzheimer's patients [6].